Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <scp>NSCLC</scp> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <scp>II</scp> Trial
Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
Haohua Zhu, Haifeng Qin, Huiyang Shi, Jingyu Lu et al.
Citations
1 citations
Journal
Thoracic Cancer
Topics
Lung Cancer Treatments and Mutations
Field-Weighted Citation Impact (FWCI)
1.52
article
Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
Haohua Zhu, Haifeng Qin, Huiyang Shi, Jingyu Lu, Xingsheng Hu, Yu Feng, Minglei Zhuo, Dongmei Lan, Junling Li, Mindy Wang, Yuankai Shi, Hongxia Zhang, Shi Jin, Jun Zhao, Guilan Dong, Kai Zhu, Zhong Dai, Meng Yang, Qingfang Shi
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Thoracic CancerVol. 16(15)
Institutions
Hengshui University (CN), Changzhi Medical College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), China-Japan Friendship Hospital (CN), Peking University Cancer Hospital (CN), Tangshan People's Hospital (CN), Beijing Luhe Hospital Affiliated to Capital Medical University (CN), Beijing Hospital (CN), Cancer Hospital of Huanxing Chaoyang District Beijing (CN), Beijing Tsinghua Chang Gung Hospital (CN), Tsinghua University (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <scp>NSCLC</scp> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <scp>II</scp> Trial — Haohua Zhu, Haifeng Qin, et al. · Thoracic Cancer (2025) | TGRS Research Map | TGRS